Compare Immunovant Inc. Common Stock (IMVT) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs JPMorgan Ultra Short Income ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 6.8× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and JPMorgan Ultra Short Income ETF for 46 Days on average.
| IMVT | JPST | |
|---|---|---|
Market Cap | $6.25B | $42.37B |
Volume | 1,755,411 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $44.96 | $50.78 |
52-Week Low | $17.03 | $50.22 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.27 with minimal daily movement (+0.04%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased holdings. The fund continues its regular $0.17 dividend payments, maintaining income distribution consistency.
JPST faces headwinds from rising interest rate environment while benefiting from demand for ultra-short duration strategies. The ETF's active management approach has shown recent underperformance versus peers, creating both opportunity for yield-seeking investors and risk from competitive pressure. Market volatility continues to drive flows into cash-alternative strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
